Elanco Animal Health Inc
ELAN evidence brief
What we can confirm
- BioSniper Score:
- 7.4 / 10
- Market Cap:
- $11.98B
- Next Catalyst:
- Earnings · Nov 6, 2026
What it means
What to watch
Prepared research question
What matters most for ELAN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELAN
Elanco Animal Health Inc (ELAN) is a global animal health company with a heritage dating back to 1954, offering a diverse portfolio of approximately 200 brands for pets and farm animals, and focusing on innovation-driven growth with recent blockbuster product launches.
Key risk: Foreign cash repatriation constraints
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 catalyst for Elanco Animal Health Inc.
Elanco Animal Health Inc (ELAN) is a global animal health company with a heritage dating back to 1954, offering a diverse portfolio of approximately 200 brands for pets and farm animals, and focusing on innovation-driven growth with recent blockbuster product launches.
- Cash & equivalents of $530.0M as of 2026-06-30 [sec].
- Total revenue of $1,368.0M and net income of $54.0M as of 2026-06-30 [sec].
- Shareholders' equity of $6,588.0M as of 2026-06-30 [sec].
- Delivered 10 consecutive quarters of underlying growth and secured approval for all six 'Big 6' blockbuster innovation products as of 2025 [sec · filed 2026-04-08].
- Generated $892M in revenue from new products launched since 2020 as of 2025 [sec · filed 2026-04-08].
What works
- Strong innovation pipeline: all six 'Big 6' blockbuster products approved in the U.S., with global expansion underway and next wave of pipeline assets expected through 2031 [sec · filed 2026-04-08].
- Consistent growth: delivered 10 consecutive quarters of underlying growth, including 9% organic constant currency revenue growth in 2025 [sec · filed 2026-04-08].
- Disciplined capital allocation: net leverage ratio reduced to 3.6x in 2025, an improvement of two turns in two years [sec · filed 2026-04-08].
- Diversified global presence: 53% of revenue from outside the U.S., serving 90+ countries with ~9,900 employees [sec · filed 2026-04-08].
What to weigh
- Significant portion of cash held outside the U.S., with potential repatriation constraints due to local regulations and income taxes [sec_mda · as of 2026-08-05].
- Net income of $54.0M on $1,368.0M revenue as of 2026-06-30 implies a relatively low net profit margin of about 3.9% [sec].
- Dependence on successful global expansion of new products like Zenrelia and Credelio Quattro, which face regulatory and market adoption risks in various countries [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
All six 'Big 6' blockbuster products approved in the U.S.
“our "Big 6" portfolio, completing a key milestone in pipeline execution. With all six products approved in the U.S.”
SEC filings · April 8, 2026
10 consecutive quarters of underlying growth
“Delivered 10 consecutive quarters of underlying growth, exceeding guidance.”
SEC filings · April 8, 2026
Net leverage ratio of 3.6x in 2025
“Reduced net leverage to 3.6x at year-end, ahead of plan.”
SEC filings · April 8, 2026
Revenue from new products launched since 2020 was $892M in 2025
“Generating $892 million of revenue from new products launched si”
SEC filings · April 8, 2026
Catalyst timeline
- 2026-11-06 · Earnings: Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement — Investors will monitor revenue growth, profitability, and pipeline updates.
Risks & what to watch (3)›
Key risks
- Foreign cash repatriation constraints — Significant cash held outside U.S.; repatriation may be limited by local regulations and taxes [sec_mda · as of 2026-08-05].
- Low net profit margin — Net income of $54M on $1,368M revenue as of 2026-06-30 yields ~3.9% margin [sec].
- Global expansion execution risk — New products Zenrelia and Credelio Quattro face regulatory and market adoption hurdles in multiple countries [sec_mda · as of 2026-08-05].
What to watch
- Global expansion progress of Zenrelia and Credelio Quattro, with additional regulatory reviews and launches in key markets [sec_mda · as of 2026-08-05].
- Next wave of pipeline assets expected through 2031, as outlined in December Investor Day [sec · filed 2026-04-08].
- Third quarter 2026 financial results announcement scheduled for 2026-11-06 [catalyst].
- Continued leverage reduction and cash management strategy, especially regarding foreign cash repatriation [sec_mda · as of 2026-08-05].
Sources: News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Elanco Animal Health Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Elanco Animal Health Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 1.06 · 1% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~23d
7 buys · 0 sells (180d)
Catalysts
Financials
Short Interest
as of Apr 28, 2026- % of float
- 7.8%
- Days to cover
- 4.1
- Shares short
- 24,563,390
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELAN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Elanco Animal Health Inc?
Elanco Animal Health Inc (ELAN) is a global animal health company with a heritage dating back to 1954, offering a diverse portfolio of approximately 200 brands for pets and farm animals, and focusing on innovation-driven growth with recent blockbuster product launches.
What is Elanco Animal Health Inc's next catalyst?
Elanco Animal Health Inc's next tracked catalyst is a Earnings event — "Earnings: Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement" — expected November 6, 2026.
Who is the CEO of Elanco Animal Health Inc?
Mr. Jeffrey N. Simmons is the chief executive officer of Elanco Animal Health Inc (ELAN).
Where is Elanco Animal Health Inc headquartered?
Elanco Animal Health Inc (ELAN) is headquartered in Indianapolis, IN, United States.
What therapeutic areas does Elanco Animal Health Inc focus on?
Elanco Animal Health Inc develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.